A comparison of contrast sensitivity in early mild and early intermediate age-related macular degeneration after adjusting for age and visual acuity

2016 ◽  
Vol 22 (4) ◽  
pp. 196-204
Author(s):  
Rasa Liutkevičienė ◽  
Rasa Čiumbaraitė ◽  
Mantas Banevičius
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Contrast Sensitivity ◽  
Visual Function ◽  
Intermediate Stage ◽  
Age Related Macular Degeneration ◽  
P Value ◽  
Age Related ◽  
Group 2 ◽  
Group 1

Background. It has been suggested that contrast sensitivity can provide valuable information about visual function in addition to visual acuity assessment. Some patients retain relatively good visual acuity, yet complain of poor vision. In these patients, other tests of visual function such as contrast sensitivity should be evaluated. Methods. We examined patients with early mild stage age-related macular degeneration (group 1), and early intermediate stage age-related macular degeneration (group 2). Digital analysis methodology was used for retina drusen localisation and its diameter measurement. Functional acuity contrast sensitivity tests (FACT) were performed using a Ginsburg Box, VSCR-CST-6500. Results. The  nighttime results without glare in group  2 were worse at 1.5, 3, 6 and 18 cycles per degree of the visual angle, the daytime results without glare were worse at 3 and 6 cycles per degree. The nighttime results with glare were worse at 1.5, 3, 6 and 18 cycles per degree, and the daytime results with glare were worse at 1.5 and 3 cycles per degree. Results after adjusting for age and visual acuity to 1.0 in the  group 1  patients were better compared to the  group 2 patients and the p value was 0.0005. Conclusions. The  test results in patients with early intermediate age-related macular degeneration, in comparison to early mild age-related macular degeneration, showed a  significant decrease mostly in the nighttime either with or without glare in high and medium spatial frequencies (cycles/degree). After adjusting for age and visual acuity the FACT results were even worse in early intermediate AMD patients.

scholarly journals Visual Function and Patient Satisfaction with Multifocal Intraocular Lenses in Patients with Glaucoma and Dry Age-Related Macular Degeneration

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Carmen Sánchez-Sánchez ◽  
Laureano A. Rementería-Capelo ◽  
Beatriz Puerto ◽  
Cristina López-Caballero ◽  
Aida Morán ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Contrast Sensitivity ◽  
Visual Function ◽  
Intraocular Lenses ◽  
Age Related Macular Degeneration ◽  
Multifocal Intraocular Lenses ◽  
Age Related ◽  
Increased Risk ◽  
Preperimetric Glaucoma

Purpose. To report visual function and self-reported satisfaction of patients with glaucoma and dry age-related macular degeneration (dAMD) implanted with multifocal intraocular lenses (MIOL). Methods. Patients with glaucoma or dAMD as well as healthy individuals implanted with MIOL were invited to participate. Explorations performed were uncorrected and corrected distance visual acuity (UDVA and CDVA), low-contrast visual acuity (LCVA), binocular contrast sensitivity, and defocus curves. Patients completed the Catquest-9 questionnaire and reported on the presence of dysphotopsias and the need for spectacles. Results. 38 subjects were included: 11 in the healthy/control group and 9 each in the preperimetric glaucoma, perimetric glaucoma, and dAMD groups. Controls had statistically better monocular UDVA, CDVA, and LCVA than patients with glaucoma and dAMD, as well as better binocular acuity in the defocus curves between −2.00 D and +0.50 D. Differences between controls and patients with preperimetric glaucoma were not statistically significant. Between −3.0 D and +0.5 D, all groups except dAMD achieved acuities better than 0.2 logMAR. Patients with dAMD had worse contrast sensitivity than all others for 3 cycles per degree (cpd), and patients with glaucoma had worse values than all others for 12 cpd; other differences did not reach statistical significance. Healthy subjects and patients with preperimetric glaucoma perceived halos more often than patients with glaucoma or dAMD, while suffering less from glare. Patients with glaucoma and dAMD found more difficulties when driving at night and required spectacles for near more often than the other subjects. Patients with dAMD were less satisfied with their vision. Conclusions. MIOLs may be implanted in patients with preperimetric glaucoma with little fear of patient dissatisfaction. In glaucoma and dAMD, MIOLs might be considered with caution, after explaining the increased risk of glare and the higher need for spectacle correction for reading.

scholarly journals The impact of saffron (Crocus sativus) supplementation on visual function in patients with dry age-related macular degeneration

2016 ◽  
Vol 10 ◽  
Author(s):  
Abbas Riazi ◽  
Yunes Panahi ◽  
Ali Agha Alishiri ◽  
Mohammad Ahmad Hosseini ◽  
Ali Akbar Karimi Zarchi ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Contrast Sensitivity ◽  
Visual Function ◽  
Low Vision ◽  
Age Related Macular Degeneration ◽  
Crocus Sativus ◽  
Control Group ◽  
Age Related ◽  
The Impact

The aim was to evaluate the impact of saffron supplementation on visual function in patients with dry age-related macular degeneration (ARMD). Fifty-four participants, 23 male and 31 female, with dry ARMD were assigned to one of the following two groups. The treatment group (n=29) consumed 50 mg saffron daily during a 3- month period, while 25 subjects served as the control group. Visual acuity, contrast sensitivity, and retinal thickness were measured at the beginning and at the end of the study. Quality of life was evaluated using the Melbourne Low Vision Index (MLVI) before and after treatment. Significant increases in visual acuity and contrast sensitivity were found in the saffron group but not in the control group. Changes in macular thickness were not statistically different between the two groups. Short-term consumption of saffron may slow down the progression of disease and improve visual function, especially contrast sensitivity, in patients with dry ARMD.

Contrast sensitivity function in patients with macular disease and good visual acuity

2021 ◽  
pp. bjophthalmol-2020-318494
Author(s):  
Karen M Wai ◽  
Filippos Vingopoulos ◽  
Itika Garg ◽  
Megan Kasetty ◽  
Rebecca F Silverman ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Contrast Sensitivity ◽  
Visual Function ◽  
Sensitivity Function ◽  
Age Related Macular Degeneration ◽  
Macular Disease ◽  
Age Related ◽  
Spatial Frequencies ◽  
Healthy Control

IntroductionContrast sensitivity function (CSF) may better estimate a patient’s visual function compared with visual acuity (VA). Our study evaluates the quick CSF (qCSF) method to measure visual function in eyes with macular disease and good letter acuity.MethodsPatients with maculopathies (retinal vein occlusion, macula-off retinal detachment, dry age-related macular degeneration and wet age-related macular degeneration) and good letter acuity (VA ≥20/30) were included. The qCSF method uses an intelligent algorithm to measure CSF across multiple spatial frequencies. All maculopathy eyes combined and individual macular disease groups were compared with healthy control eyes. Main outcomes included area under the log CSF (AULCSF) and six CS thresholds ranging from 1 cycle per degree (cpd) to 18 cpd.Results151 eyes with maculopathy and 93 control eyes with VA ≥20/30 were included. The presence of a maculopathy was associated with significant reduction in AULCSF (β: −0.174; p<0.001) and CS thresholds at all spatial frequencies except for 18 cpd (β: −0.094 to −0.200 log CS, all p<0.01) compared with controls. Reductions in CS thresholds were most notable at low and intermediate spatial frequencies (1.5 cpd, 3 cpd and 6 cpd).ConclusionCSF measured with the qCSF active learning method was found to be significantly reduced in eyes affected by macular disease despite good VA compared with healthy control eyes. The qCSF method is a promising clinical tool to quantify subtle visual deficits that may otherwise go unrecognised by current testing methods.

scholarly journals Association of Vision-related Quality of Life with Visual Function in Age-Related Macular Degeneration

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Susanne G. Pondorfer ◽  
Jan. H. Terheyden ◽  
Manuel Heinemann ◽  
Maximilian W. M. Wintergerst ◽  
Frank G. Holz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Macular Degeneration ◽  
Contrast Sensitivity ◽  
Visual Function ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Related Quality ◽  
The Impact

Abstract The purpose of this study was to assess which visual function measures are most strongly associated with vision-related quality of life (VRQoL) in age-related macular degeneration (AMD). A cross-sectional study of subjects with early AMD (n = 10), intermediate AMD (n = 42) and late AMD (n = 38) was conducted. Subjects were interviewed with the Impact of Vision Impairment (IVI) questionnaire. Functional tests performed included best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA), visual acuity measured with the Moorfields Acuity Charts (MAC), contrast sensitivity, reading speed, mesopic and dark-adapted microperimetry. The relationship between VRQoL and visual function was assessed with multiple regressions controlling for confounders. Rasch analysis demonstrated the validity of the IVI to assess VRQoL through three subscales: reading and accessing information, mobility and independence, and emotional well-being. Subjects with late AMD had significant lower IVI scores on all subscales compared with intermediate and early AMD (p < 0.011). In the overall cohort, IVI subscales were associated with BCVA, LLVA, MAC-VA and contrast sensitivity (all p < 0.001). Among the subgroup of early and intermediate AMD subjects, reading and mobility subscales were significantly associated with MAC-VA (p < 0.013). These results suggest that MAC-VA is a useful, patient-relevant measure of visual impairment in AMD.

scholarly journals Effect of Ranibizumab Treatment in Cases of Choroidal Neovascular Membranes Secondary to Pathological Myopia versus Age-Related Macular Degeneration

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
M S Abdaltawab ◽  
Z F Ismail ◽  
W M A Ebeid ◽  
S M Fawzy
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
P Value ◽  
Newly Diagnosed ◽  
Pathological Myopia ◽  
Age Related ◽  
Significant Difference ◽  
The Mean

Abstract Aim of the Work The aim of this work is to compare the response of treatment with ranibizumab in terms of visual acuity in cases of CNV secondary to pathological myopia versus CNV secondary to age-related macular degeneration. Methods This prospective, comparative study included ten eyes newly diagnosed as having CNV secondary to pathological myopia, and 10 eyes newly diagnosed as having subfoveal active CNV secondary to AMD. All patients had 3 monthly intravitreal Injections of 0.50 mg (in 0.05 ml of solution) ranibizumab with monthly evaluation of best corrected visual acuity (BCVA) by Landolt C chart, and also calculated in Logarithm of Minimum Angle of Resolution (Log MAR). Results pretreatment there was no significant difference between the two groups as the mean VA (Log Mar) was 1.31 ± 0.2 in AMD group and 1.17 ± 0.3 in MCNV group of P value = 0.431 and also post three IVI of ranibizumab showed no significant difference between the two groups as the mean VA (Log Mar) was 1.22 ± 0.2 for AMD and 1.22 ± 0.5 for MCNV of P value = 0.635. Conclusion there was no significant difference in BCVA between AMD and MCNV groups after three intravitreal injections of ranibizumab.

Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration

2003 ◽  
Vol 241 (12) ◽  
pp. 968-974 ◽  
Author(s):  
Caren Bellmann ◽  
Kristina Unnebrink ◽  
Gary S. Rubin ◽  
Daniel Miller ◽  
Frank G. Holz
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Contrast Sensitivity ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration

2016 ◽  
Vol 95 (4) ◽  
pp. e270-e277 ◽  
Author(s):  
Graham F. Merry ◽  
Marion R. Munk ◽  
Robert S. Dotson ◽  
Michael G. Walker ◽  
Robert G. Devenyi
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Contrast Sensitivity ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Visual acuity dynamics after phacoemulsification in patients with “wet” form of age-related macular degeneration, treated by intravitreal angiogenesis inhibitor injections

2013 ◽  
Vol 6 (1) ◽  
pp. 44-50 ◽  
Author(s):  
Natalya Viktorovna Chistyakova ◽  
Yuriy Sergeevich Astakhov ◽  
Nikita Yuryevich Dal
Keyword(s):  
Visual Acuity ◽  
Cataract Surgery ◽  
Macular Degeneration ◽  
Angiogenesis Inhibitor ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
The Mean ◽  
The Difference ◽  
Group 2 ◽  
Wet Amd

Design: prospective non-randomized experimental longitudinal cohort study. The aim of the study: to evaluate the visual acuity after phacoemulsification in patients with the “wet” form of age-related macular degeneration, treated by intravitreal angiogenesis inhibitor injections. Materials: 48 patients (48 eyes) with the “wet” form of AMD, treated by intravitreal angiogenesis inhibitor injections, and incipient cataract. All eyes in the study had a diagnosis of “wet” AMD and underwent cataract surgery. They were followed for a minimum of two years after the cataract surgery. The mean age of patients was 78.16 ± 5 years. There were 36 female (75 %) and 12 male (25 %) patients. Results: All patients were retrospectively divided into two groups. Group No. 1 consisted of 23 patients — operated within a year of the diagnosis of “wet” AMD, and group No. 2 which consisted of 25 patients who had a diagnosis of “wet” AMD for longer than one year prior to the cataract surgery. The mean preoperative visual acuity in the 1st group was 0.16 ± 0.07 (median 0.15), and in patients of group 2 — 0.23 ± 0.06 (median 0,2). Mean visual acuity immediately before surgery in the 1st group was 0.13 ± 0.04 (median 0.09), in the 2nd group — 0.12 ± 0.04 (median 0,08). After surgery, in the 1st group, mean visual acuity was — 0.28 ± 0.08 (median 0.25), in the 2nd group —0.18 ± 0.07 (median 0,15). The difference between the two groups was statistically significant, p < 0.01, t-test. Statistically significant visual acuity increase after surgery was registered in both groups and was preserved after one and two years, when compared to the data before surgery: for the 1st group — 0.13 and 0.1; for the 2nd group — 0,1 and 0.07, respectively (p < 0,01, Wilcoxon criterion). Conclusions: Phacoemulsification is reasonable for eyes with the “wet” form of age-related macular degeneration. Patients with shorter “wet” AMD duration obtain a higher visual acuity increase after cataract surgery. Statistically significant visual acuity increase after surgery is preserved in the majority of patients during next 2 years of follow-up.

scholarly journals Modulated anti-VEGF therapy under the influence of lipid metabolizing proteins in Age related macular degeneration: a pilot study

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Kaushal Sharma ◽  
Priya Battu ◽  
Ramandeep Singh ◽  
Suresh Kumar Sharma ◽  
Akshay Anand
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Vision Loss ◽  
Retinal Disease ◽  
Age Related Macular Degeneration ◽  
Clinical Images ◽  
Anti Vegf ◽  
Age Related ◽  
Wet Amd ◽  
Group 1

AbstractAge-related macular degeneration (AMD) is a devastating retinal disease that results in irreversible vision loss in the aged population. The complex genetic nature and degree of genetic penetrance require a redefinition of the current therapeutic strategy for AMD. We aimed to investigate the role of modifiers for current anti-VEGF therapy especially for non-responder AMD patients. We recruited 78 wet AMD cases (out of 278 AMD patients) with their socio-demographic and treatment regimen. Serum protein levels were estimated by ELISA in AMD patients. Data pertaining to the number of anti-VEGF injections given (in 1 year) along with clinical images (FFA and OCT) of AMD patients were also included. Visual acuity data (logMAR) for 46 wet AMD cases out of a total of 78 patients were also retrieved to examine the response of anti-VEGF injections in wet AMD cases. Lipid metabolizing genes (LIPC and APOE) have been identified as chief biomarkers for anti-VEGF response in AMD patients. Both genotypes ‘CC’ and ‘GC’ of LIPC have found to be associated with a number of anti-VEGF injections in AMD patients which could influence the expression of B3GALTL,HTRA1, IER3, LIPC and SLC16A8 proteins in patients bearing both genotypes as compared to reference genotype. Elevated levels of APOE were also observed in group 2 wet AMD patients as compared to group 1 suggesting the significance of APOE levels in anti-VEGF response. The genotype of B3GALTL has also been shown to have a significant association with the number of anti-VEGF injections. Moreover, visual acuity of group 1 (≤ 4 anti-VEGF injections/year) AMD patients was found significantly improved after 3 doses of anti-VEGF injections and maintained longitudinally as compared to groups 2 and 3. Lipid metabolising genes may impact the outcome of anti-VEGF AMD treatment.

Sign in / Sign up

Export Citation Format

Share Document